UARK 91-004 Therapeutic Research in Multiple Myeloma
18 Years
N/A
Both
Multiple Myeloma
Trial Information
UARK 91-004 Therapeutic Research in Multiple Myeloma
Participating in this study will require that blood and bone marrow samples be obtained as a
part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral
blood/tissue samples will be collected for research purposes, as well as testing for genetic
traits of Castleman's disease if you consent to this study. In addition, data will be
collected including demographic information gathered from your medical record, including
gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results,
treatment protocols, dates of relapses, subsequent treatment protocols, and current
treatments and medications.
Inclusion Criteria:
- Any subject evaluated for a MIRT protocol
Exclusion Criteria:
- Subjects who have not been evaluated for a MIRT protocol
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Principal Investigator
Bart Barlogie, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UAMS Myeloma Institute for Research and Therapy
Authority:
United States: Institutional Review Board
Study ID:
UARK 91-004
NCT ID:
NCT00572338
Start Date:
August 2003
Completion Date:
December 2015
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| University of Arkansas for Medical Sciences/MIRT | Little Rock, Arkansas 72205 |
